A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
An Anti-TNF Failure Sub-study was initiated (recruited separately from Main study) using the same treatment as the Main study in order to assess the immunogenicity and safety in the Anti-TNF Failure population. The Sub-study terminated due to low recruitment and participants were permitted to roll into the LT Open Label Period.
Long Beach, California 90806, United States
Asheville, North Carolina 28801, United States
Sugarland, Texas 77479, United States
Buenos Aires, Buenos Aires 1015, Argentina
Buenos Aires, Buenos Aires 1426, Argentina
Buenos Aires, Buenos Aires C1428DQG, Argentina
Ciudad Autonoma, Buenos Aires CP1425A WC, Argentina
Rosario, Santa Fe, Santa Fe Province 2000, Argentina
Ste-Foy, Quebec G1V 3M7, Canada
Ste-Foy, Quebec G1W 4R4, Canada
Heraklion Crete, 71110, Greece
Secunderabad, Andhra Pradesh 500003, India
Muckleneuk, Gauteng 0002, South Africa
Muckleneuk, Gauteng 0132, South Africa
Panorama, Western Cape 7500, South Africa